TThe Global Canine Atopic Dermatitis Market size was estimated at USD 1005.90 million in 2020 and is expected to reach USD 1666 million and witness a CAGR of 9.0% during the forecast period. Increasing incidences of atopic dermatitis in dogs fueled by air pollution and allergens is the key driver for this market. The most common symptoms associated with atopic dermatitis are scratching, itching, foul odour, loss of hair, scaly skin, etc. The breeds found to be most susceptible to this canine atopic dermatitis are Golden Retriever, German shepherd, Labrador, andPug. Rapid industrialization in the developing and developed countries is anticipated to further propel the market growth.
According to the American College of Veterinary Dermatology (ACVD) report, around 10% to 15% of dogs suffered from this canine atopic dermatitis in 2017. The x of this disease is not completely understood yet, though genetic abnormalities are reported to be one of the major reasons behind it. According to a study by the American Journal of Veterinary Research, the risk to develop canine atopic dermatitis in golden retrievers was around 50% in the U.K. due to geographic variation, which is expected to bolster the revenue in the coming years.
On the basis of product, the canine atopic dermatitis treatment market is segmented into glucocorticoids, antihistamines, immunosuppressants, MAbs, and others. Glucocorticoids dominated the market in terms of revenue in 2020, owing to its increased usage and cheaper cost. Topical and oral glucocorticoids were found to be the first line of treatment for the management of canine atopic dermatitis. Oral prednisone, prednisolone, and methylprednisolone are usually preferred for the treatment of acute flares. The side effects are also minimal as compared to other dosage forms.
On the basis of mode of administration, the canine atopic dermatitis market is segmented into oral, topical, and injectable. The oral segment held the largest revenue share in 2020 owing to its lesser price. Moreover, it is more convenient as compared to injectable and topical modes. The dog owners can administer the drugs by themselves which is further fueling its demand.
By the distribution channel, the canine atopic dermatitis treatment market is segmented into veterinary hospitals/clinics, retail, and e-commerce. The retail segment dominated the market in 2020 owing to increased product availability. The advent of retail pharmacy chains is a major contributor to the share of the distribution channel segment. Adoption of digitalized systems in retail pharmacies to reduce risk of errors in the prescriptions is anticipated to propel the revenue growth over the coming years. Moreover, veterinarians have begun to rely on general pharmacies to fill prescriptions for drugs, which are not available in vet pharmacies, which is further propelling the market growth.
The Canine Atopic Dermatitis Market is segmented on the basis of product, mode of administration, distribution channel, and region. On the basis of Product Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others. On the basis of mode of administration Topical, Oral, Injectable. On the basis of distribution channel Veterinary Hospitals/Clinics, Retail, E-commerce.
North America dominated the regional market in 2020 and is anticipated to witness the same trend over the forecast period. This growth can be attributed to the increasing incidence of canine atopic dermatitis in pet dogs, new product launches, and growing concern among pet owners. The rising pet ownership is further boosting the market growth. Furthermore, there is high investment in the development of new drugs by major players, which is expected to propel the growth over the forecast period.
According to the American College of Veterinary Dermatology (ACVD) report, around 10% to 15% of dogs suffered from this canine atopic dermatitis in 2017. The x of this disease is not completely understood yet, though genetic abnormalities are reported to be one of the major reasons behind it. According to a study by the American Journal of Veterinary Research, the risk to develop canine atopic dermatitis in golden retrievers was around 50% in the U.K. due to geographic variation, which is expected to bolster the revenue in the coming years.
On the basis of product, the canine atopic dermatitis treatment market is segmented into glucocorticoids, antihistamines, immunosuppressants, MAbs, and others. Glucocorticoids dominated the market in terms of revenue in 2020, owing to its increased usage and cheaper cost. Topical and oral glucocorticoids were found to be the first line of treatment for the management of canine atopic dermatitis. Oral prednisone, prednisolone, and methylprednisolone are usually preferred for the treatment of acute flares. The side effects are also minimal as compared to other dosage forms.
On the basis of mode of administration, the canine atopic dermatitis market is segmented into oral, topical, and injectable. The oral segment held the largest revenue share in 2020 owing to its lesser price. Moreover, it is more convenient as compared to injectable and topical modes. The dog owners can administer the drugs by themselves which is further fueling its demand.
By the distribution channel, the canine atopic dermatitis treatment market is segmented into veterinary hospitals/clinics, retail, and e-commerce. The retail segment dominated the market in 2020 owing to increased product availability. The advent of retail pharmacy chains is a major contributor to the share of the distribution channel segment. Adoption of digitalized systems in retail pharmacies to reduce risk of errors in the prescriptions is anticipated to propel the revenue growth over the coming years. Moreover, veterinarians have begun to rely on general pharmacies to fill prescriptions for drugs, which are not available in vet pharmacies, which is further propelling the market growth.
The Canine Atopic Dermatitis Market is segmented on the basis of product, mode of administration, distribution channel, and region. On the basis of Product Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others. On the basis of mode of administration Topical, Oral, Injectable. On the basis of distribution channel Veterinary Hospitals/Clinics, Retail, E-commerce.
North America dominated the regional market in 2020 and is anticipated to witness the same trend over the forecast period. This growth can be attributed to the increasing incidence of canine atopic dermatitis in pet dogs, new product launches, and growing concern among pet owners. The rising pet ownership is further boosting the market growth. Furthermore, there is high investment in the development of new drugs by major players, which is expected to propel the growth over the forecast period.
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
